Market Place
Sourcing Support
Sandoz Resolves US Generic Drug Antitrust Litigation
17 Dec 2024 //
GLOBENEWSWIRE
FDA updates label of 33-year-old cancer drug with dose & warning
21 Nov 2024 //
ENDPTS
FDA Updates Label Of 33-Year-Old Cancer Drug With Warning
20 Nov 2024 //
ENDPTS
Agomab Announces Appointment of Former Sandoz CFO
18 Nov 2024 //
BUSINESSWIRE
EC grants approval to Sandoz’s biosimilar to treat retinal diseases
16 Nov 2024 //
FINANCIALXPRESS
Sandoz Receives EC Approval for Afqlir® Biosimilar
15 Nov 2024 //
GLOBENEWSWIRE
Sandoz reports third-quarter and nine-month 2024 sales
30 Oct 2024 //
GLOBENEWSWIRE
Sandoz`s Biologic Jubbonti (Denosumab-bbdz) Receives Suppl Approval in US
24 Oct 2024 //
FDA
Sandoz`s Biologic Wyost (Denosumab-bbdz) Receives Suppl Approval in US
24 Oct 2024 //
FDA
Sandoz`s Biologic Zarxio (Filgrastim) Receives Suppl. Approval in US
22 Oct 2024 //
FDA
Sandoz US launches generic paclitaxel in single-dose vial
11 Oct 2024 //
GLOBENEWSWIRE
Sandoz And Liquidia Win $137M Against United In Remodulin Dispute
16 Sep 2024 //
FIERCE PHARMA
As Sandoz contract winds down, GSK will close antibiotics plant in UK
10 Sep 2024 //
FIERCE PHARMA
Regeneron takes on Sandoz over newly-approved Eylea copycat
29 Aug 2024 //
BLOOMBERG
Axsome Settles Sunosi Patent Litigation With Sandoz
21 Aug 2024 //
GLOBENEWSWIRE
Sandoz Gets FDA Approval For Enzeevu, Boosting US Biosimilar Position
12 Aug 2024 //
GLOBENEWSWIRE
Sandoz reports second-quarter sales and half-year 2024 results
08 Aug 2024 //
GLOBENEWSWIRE
Sandoz Launches Biosimilar Pyzchiva For Chronic Inflammatory Diseases
24 Jul 2024 //
GLOBENEWSWIRE
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
08 Jul 2024 //
ACCESSWIRE
FDA approves biosimilar Pyzchiva (Ustekinumab-ttwe), to be commercialized in US
01 Jul 2024 //
GLOBENEWSWIRE
Sandoz Inc Biologic Adalimumab-Adaz Receives Supp Approval in US
12 Jun 2024 //
FDA
EC approves Sandoz’s biosimilars for bone-related ailments
23 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Sandoz’s Wyost and Jubbonti Granted EC Marketing Authorization
22 May 2024 //
GLOBENEWSWIRE
Health Canada Issues Recall of Sandoz`s Fesoterodine Fumarate
16 May 2024 //
HEALTH CANADA
Ex-Sandoz exec gets probation for price-fixing after cooperation deal
16 May 2024 //
REUTERS
Sandoz reports first quarter 2024 sales
07 May 2024 //
GLOBENEWSWIRE
Amid promising launch of Humira biosim, Sandoz sees 6% growth
07 May 2024 //
FIERCE PHARMA
Sandoz reaches agreement with Amgen over patent dispute
01 May 2024 //
REUTERS
Sandoz AGM Approves All Board Proposed Resolutions
30 Apr 2024 //
GLOBENEWSWIRE
Bayer`s patent for blood thinner Xarelto invalid, UK court rules
13 Apr 2024 //
REUTERS
Sandoz opens new production facility in Austria for life-saving medicines
21 Mar 2024 //
GLOBENEWSWIRE
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
13 Mar 2024 //
GLOBENEWSWIRE
Sandoz wins FDA approval for first two biosimilars for Amgen`s bone drug
06 Mar 2024 //
ENDPTS
Sandoz announces nominations to the Board of Directors and leadership change
05 Mar 2024 //
GLOBENEWSWIRE
Sandoz receives FDA approval for first and only denosumab biosimilars
05 Mar 2024 //
GLOBENEWSWIRE
Sandoz`s Biologic Jubbonti (denosumab-bbdz) Receives Approval in the U.S.
05 Mar 2024 //
FDA
Sandoz acquires CIMERLI® business from Coherus
04 Mar 2024 //
GLOBENEWSWIRE
Sandoz US subsidiaries resolve generic drug antitrust class action litigation
29 Feb 2024 //
GLOBENEWSWIRE
Sandoz enters $265 mln settlement agreement in U.S. price-fixing case
29 Feb 2024 //
REUTERS
House Dems seek briefings with Pfizer, Sandoz and Teva on ongoing drug shortages
22 Feb 2024 //
ENDPTS
Biocon Biologics partners with Sandoz Australia for Biosimilars
10 Feb 2024 //
INDIAN PHARMA POST
Sandoz to shutter Eon Labs site acquired nearly 20 years ago
09 Feb 2024 //
FIERCE PHARMA
Sandoz announces changes in the Board of Directors
01 Feb 2024 //
GLOBENEWSWIRE
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko
31 Jan 2024 //
GLOBENEWSWIRE
Sandoz announces agreement to acquire CIMERLI® business from Coherus
22 Jan 2024 //
GLOBENEWSWIRE
Sandoz buys Coherus` Lucentis biosimilar Cimerli for $170M
22 Jan 2024 //
FIERCE PHARMA
Sandoz` Erelzi (etanercept) Receives Approval in Europe
14 Dec 2023 //
EMA
Sandoz breaks ground at $400M Slovenia site
13 Dec 2023 //
FIERCE PHARMA
Novartis unveils new brand identity after Sandoz spinoff
06 Dec 2023 //
ENDPTS
Sandoz`s Herwenda (trastuzumab) Receives Approval in Europe
23 Nov 2023 //
EMA
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe
21 Nov 2023 //
GLOBENEWSWIRE
Sandoz`s Tyruko (natalizumab) Receives Approval in Europe
20 Nov 2023 //
EMA
Sandoz opens two new facilities; Gates Foundation funds needle-free vaccines
16 Nov 2023 //
ENDPTS
Sandoz inaugurates new antibiotic production plant in Austria
10 Nov 2023 //
GLOBENEWSWIRE
Updated: Novartis `on track` to complete restructuring post Sandoz spin
24 Oct 2023 //
ENDPTS
Sandoz reports year-to-date sales for the first nine months of 2023
24 Oct 2023 //
GLOBENEWSWIRE
Sandoz`s Tyruko (natalizumab) Receives Approval in Europe
17 Oct 2023 //
EMA
Sandoz B2B`s Generic Sugammadex Receives Approval in the U.S.
13 Oct 2023 //
FDA
Sandoz`s Biologic Ziextenzo (pegfilgrastim) Receives Approval in the U.S.
09 Oct 2023 //
FDA
